Colorectal Neuroendocrine Neoplasm
Associated Genetic Biomarkers
NCI Definition: A neoplasm with neuroendocrine differentiation that arises from the colon or rectum. It includes well differentiated neuroendocrine tumors (low and intermediate grade) and poorly differentiated neuroendocrine carcinomas (high grade). 
Colorectal neuroendocrine neoplasms most frequently harbor alterations in TP53, APC, KRAS, RB1, and BRAF .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, APC Mutation, and KRAS Mutation are the most common alterations in colorectal neuroendocrine neoplasm .
There is 1 clinical trial for colorectal neuroendocrine neoplasm, of which 1 is open and 0 are completed or closed. Of the trial that contains colorectal neuroendocrine neoplasm as an inclusion criterion, 1 is phase 1/phase 2 (1 open).
SSTR1, SSTR2, and SSTR3 are the most frequent gene inclusion criteria for colorectal neuroendocrine neoplasm clinical trials .
177lu-opsc001 is the most common intervention in colorectal neuroendocrine neoplasm clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.